Global Autism Treatment Market – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2016 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Autism Treatment Market: By Autism Type (Autistic Disorder, Asperger Syndrome, Pervasive Developmental Disorder, Childhood Disintegrative Disorder); By Treatment Approach (Behavioural Approaches, Early Intervention, Medication, Dietary Approach) By Drug  (Risperidone, Aripiprazole, Clozapine, Haloperidol, Sertraline, Methylphenidate, Venlafaxine, Fluoxetine, Others), By Geography 

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

Autism Treatment Market size was valued at USD 28,723.6 million in 2021, growing at a CAGR of 4.9% from 2022 to 2028. The global market provides a detailed overview and that can be segmented by autism type, by treatment approach, and by drug. By autism type, the global autism treatment market has been segmented into Autistic Disorder, Asperger Syndrome, Pervasive Developmental Disorder, and Childhood Disintegrative Disorder. The Autistic Disorder segment is likely to be the largest and fastest-growing segment in terms of type in 2021 due to the high prevalence of this disease. Based on treatment approach, the market is segmented into Behavioural Approaches, Early Intervention, Medication, and Dietary Approach. Among these, the Behavioural Approaches segment is expected to have the fastest-growing market during the forecast period 2022-2028 according to precision business insights. Based on drug, the global autism treatment market is segmented into Risperidone, Aripiprazole, Clozapine, Haloperidol, Sertraline, Methylphenidate, Venlafaxine, Fluoxetine, and Others. The Risperidone segment accounts for the largest share in 2021 and expected to maintain the trend in the upcoming years. It is attributed to increased focus and decreased hyperactivity in the patient. Autism spectrum disorder, or pervasive developmental disorders (PDDs), are neurodevelopmental disorders which is subjective disability in a social association, debilitated correspondence, and stereotyped examples of conduct. The most well-known types of PDD are autistic issue, Asperger’s issue, and unavoidable formative issue not generally indicated (PDD NOS). The increased prevalence of autism is anticipated to create demand for autism treatment market.

Key Development:

In Oct 2022, AXA Health launched neurodiversity services for group PMI

In May 2022, Group launched mobile application for Autism therapy in Nigeria.

Autism Treatment Market

MARKET SUMMARY
-
4.9%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 4.9%
  • Largest Market– Asia-Pacific
  • Fastest Growing Market– North-America

Autism Treatment Market

  • The global autism treatment market report gives comprehensive outlook across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
  • The report on global autism treatment market gives historical, current, and future market sizes (US$ Mn) on the basis of autism type, treatment, drugs and geographical regions.
Key Players
  • Pfizer, Inc.
  • Sanofi
  • Boehringer Ingelheim
  • Novartis International AG
  • GlaxoSmithKline plc
Autism Treatment Market Drivers

Growing predominance of a mental imbalance and Pervasive Developmental Disorder (PDD) and rising mindfulness are anticipated to propel the market growth over the forecast years.


North-America got Significant Share

Autism Treatment Market

By region, the North America is expected to witness the highest market share during the forecast period it holds a tremendous potential market for global autism treatment due to increasing number of autism treatment dealers.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East
Autism Treatment Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The fastest-growing segment of the global autism treatment market is Autistic disorder due to high prevalence of this disease.

Increased Exploration into Enzyme Replacement Therapy (ERT) is the new key trend in the global market.

Rising prevalence of the condition and awareness regarding treatment in emerging countries are the key opportunity for the global players to expand in the untapped region.

Lack of approved drugs in the market may hamper the global market growth.


Report

Company Profile

  • Pfizer, Inc. (U.S.)
  • Sanofi (France)
  • Boehringer Ingelheim (Germany)
  • Novartis International AG (Switzerland)
  • GlaxoSmithKline plc (U.K.)
  • Bristol-Myers Squibb (U.S.)
  • Teva Pharmaceutical Industries Ltd.(Israel)
  • Aurobindo Pharma Limited (India)
  • Eli Lilly and Company (U.S.)
  • AbbVie Inc. (U.S.).
  • Merck & Co., Inc. (U.S.)

Description

Autism Treatment Market size was valued at USD 28,723.6 million in 2021, growing at a CAGR of 4.9% from 2022 to 2028. The global market provides a detailed overview and that can be segmented by autism type, by treatment approach, and by drug. By autism type, the global autism treatment market has been segmented into Autistic Disorder, Asperger Syndrome, Pervasive Developmental Disorder, and Childhood Disintegrative Disorder. The Autistic Disorder segment is likely to be the largest and fastest-growing segment in terms of type in 2021 due to the high prevalence of this disease. Based on treatment approach, the market is segmented into Behavioural Approaches, Early Intervention, Medication, and Dietary Approach. Among these, the Behavioural Approaches segment is expected to have the fastest-growing market during the forecast period 2022-2028 according to precision business insights. Based on drug, the global autism treatment market is segmented into Risperidone, Aripiprazole, Clozapine, Haloperidol, Sertraline, Methylphenidate, Venlafaxine, Fluoxetine, and Others. The Risperidone segment accounts for the largest share in 2021 and expected to maintain the trend in the upcoming years. It is attributed to increased focus and decreased hyperactivity in the patient. Autism spectrum disorder, or pervasive developmental disorders (PDDs), are neurodevelopmental disorders which is subjective disability in a social association, debilitated correspondence, and stereotyped examples of conduct. The most well-known types of PDD are autistic issue, Asperger’s issue, and unavoidable formative issue not generally indicated (PDD NOS). The increased prevalence of autism is anticipated to create demand for autism treatment market.

Key Development:

In Oct 2022, AXA Health launched neurodiversity services for group PMI

In May 2022, Group launched mobile application for Autism therapy in Nigeria.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX